Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Urinalysis instrumentation, 2025

[one_third]

[/one_third]

[one_third]

[/one_third]

[one_third_last]

[/one_third_last]

[wpdatatable id=120]

[one_third]

[/one_third]
[two_third_last]

On value, preanalytics, and personnel in urinalysis

March 2025—Urinalysis reflex rules, reimbursement, instruments, research, and specimen handling and transport are some of what came up in the Jan. 15 roundtable with eight participants online and CAP TODAY publisher Bob McGonnagle leading the discussion. What they told CAP TODAY begins here, and our revised guide to urinalysis instrumentation is here.

In our urinalysis roundtable last year there was emphasis on reflex testing as a solution to some of the need for efficiency in the urinalysis workflow. Of course, people in pharmacy and the infectious disease physicians have different views about reflex criteria in urinalysis. We also talked about the need for working rules in the interest of efficiency and workflow amid automation and artificial intelligence. Lastly, we talked about the science of urinalysis, which seems to be underappreciated in the United States. Jason Anderson, can you comment on the current relevancy of those themes?

Jason M. Anderson, MPH, MT(ASCP), senior product manager, urinalysis solutions IVD product marketing, Sysmex America: Reflex testing, when done appropriately, can provide a host of benefits, from improved laboratory efficiency to more timely information for clinicians and ultimately a higher standard of patient care. Determining optimal reflex algorithms can be a challenge. Laboratory practice in urinalysis is not always standardized. Even within an integrated health network, you might see the use of different cutoffs or reflex rules at different facilities. Establishing reflex rules, agreeing on those with the various stakeholders, and making sure they’re optimized and evidence-based to the specific patient populations served are key.

With the progress of AI, machine learning, and expert system disciplines, in conjunction with increasing evidence-based outcome data, I believe we’ll see a strong emphasis on developing even more powerful and advanced reflex testing algorithms that are population specific in many cases. Add to this that analyzer technology is allowing for greater standardization, sensitivity, and specificity in laboratory testing and I see a recipe for making a positive impact on patient care.

Continue reading …
[/two_third_last]